CN101559179A - Antihypertensive peptide composition - Google Patents
Antihypertensive peptide composition Download PDFInfo
- Publication number
- CN101559179A CN101559179A CNA200810052806XA CN200810052806A CN101559179A CN 101559179 A CN101559179 A CN 101559179A CN A200810052806X A CNA200810052806X A CN A200810052806XA CN 200810052806 A CN200810052806 A CN 200810052806A CN 101559179 A CN101559179 A CN 101559179A
- Authority
- CN
- China
- Prior art keywords
- peptide
- blood pressure
- antihypertensive
- peptide composition
- antihypertensive peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention discloses an antihypertensive peptide composition with no toxic side effects but obvious effect. The antihypertensive peptide composition is realized by adopting the following technical scheme that the antihypertensive peptide composition comprises the following components according to the parts by weight: 40-70 percent of mung bean peptide and 30-60 percent of corn peptide. The antihypertensive peptide composition adopting the source of food has high security and no side effect; and the antihypertensive peptide composition plays the role of lowering the blood pressure for the patients with high blood pressure and has no action of lowering the blood pressure of the people with normal blood pressure.
Description
Technical field
The present invention relates to the peptide composition field, more particularly, relate to a kind of peptide composition with better antihypertensive effect.
Background technology
Hypertension is one of modal cardiovascular disease in the world today, and depressor market always also is " military strategist in ancient China " hotly contested spot.Epidemiological study shows that there are hyperpietic 600,000,000 people in the whole world at present, and the hypertension prevalence is about 10%, and China's hypertension prevalence is about 12%, and existing hyperpietic's number surpasses 100,000,000 people, and is the gesture that increases year by year.In case suffer from hypertension medication throughout one's life, this makes depressor market have growth potential.Interrelated data shows that by 2007, global depressor market will estimate that annual rate of growth will remain on 7% above 52,000,000,000 dollars.Therefore, each big drugmaker of the world is all researching and developing depressor as opera involving much singing and action.
The medication of the resisting hypertension of chemosynthesis class in the market can be divided into diuretic (as hydrochlorothiazide), angiotensin converting enzyme inhibitor (as captopril), beta-blocker (as labetalol), calcium channel blocker (as felodipine) and α receptor blocking agent (as prazosin) five big classes, has more than 100 description.Yet this type of chemosynthesis class medicine can produce certain side effect.
In recent years, studies show that some little peptides that discharge in the original sequence of protein also have different physiological roles, these little peptides can directly be absorbed by the body by the degraded of intestinal plurality of enzymes system.Functional peptide is varied, as promoting calcium absorption peptide, blood pressure lowering peptide, blood fat reducing peptide, immunomodulatory peptides etc.The research of the blood pressure lowering peptide focus of bioactive peptide research especially particularly.The American Studies personnel report that the earliest soybean polypeptide has the cholesterol of inhibition and raises and effect for reducing blood fat; The Japan scholar proposes oral a certain amount of soybean polypeptide and can eliminate muscle fatigue and brain fag or the like; U.S. FDA had been ratified all food that contains more than the soybean polypeptide 800mg (or soybean protein isolate 20mg) all can indicate " food useful to cardiovascular " on its labeling printed words already in 1998.This shows that the health-care effect of soybean polypeptide has obtained the approval of united states drug regulator.In addition, the Japanese manufacturer sesame cake meal that will press Oleum sesami obtains a kind of novel polypeptide behind enzymatic hydrolysis---the Semen Sesami polypeptide.Result of study shows that the Semen Sesami polypeptide has outstanding blood pressure lowering effect, and gives out natural fragrance, so the Semen Sesami polypeptide can directly be processed into health food, is a kind of natural antihypertensive health care product.
The polypeptide series products has become the raw material " new lover " of international market situation of selling well medicine or health food rapidly since the nineties in last century.In Europe, 93% polypeptide raw material is used to produce various curatives, and all the other 7% are health food or cosmetic use.Data according to statistics, European polypeptide series products total sales volume in 2004 (is amounted to 400,000,000 dollars) up to 300,000,000 Euros, and the sales volume of expecting 2005 also will be above this numeral.If the rate of increase by annual average 10% calculates, the polypeptide products total sales volume of European market to 2012 year will reach hundred million Euros of 6-7.The polypeptide series products market sales revenue has more than 10 hundred million dollars approximately on the international market at present.The U.S. and the Japanese two big polypeptide series products markets that become after the European market.
At present, there has been the blood pressure lowering peptide product in multiple different material source to appear on the market.Comprising: Wuhan 9 Health and Biological Engineering Co., Ltd. utilizes and extracts enzymatic hydrolysis of soybean separating medium development soybean polypeptide oral liquid, has blood pressure regulation, appetite strengthening, enhancing immunity improves effects such as human intestines and stomach's dysfunction; Jiangsu section clever literary composition biological engineering company limited is developed the casein blood pressure lowering peptide; China Chinese medicine and pharmacy cerebrovascular scientific research institute adopts the plant gene extractive technique directly to extract the plain and concentrated nanometer blood pressure lowering peptide that is refined into of vegetable active molecule compatibility import kinase of Gene regulation in conjunction with liquid as chromatograph from tens kinds of pure natural medical herbs.It contains 40 several amino acids, 30 various trace elements and ten several mineral materials, and its mechanism of action and effect and the single controlling blood pressure of conventional blood pressure lowering medicine belong to diverse two notions.In addition, biotechnology research institute of the good everyday biological Technology Dev Company Ltd. in Wuhan is by self advanced person's technology such as enzymolysis, utilizes that the brown paulownia development of resources of enriching has gone out brown paulownia peptide, palm fibre is put functional mass such as albumen.Simultaneously, utilize the garbage of domestic marine organisms such as fish and shrimp etc. to develop serial marine peptide series of products.To structure, screening and the application in assortment of genes peptide storehouse and chemical combination peptide storehouse, and in conjunction with the raw material of other natural origin, as plant extract, the tangible antihypertensive product of exploitation no side effects and action effect is just at the early-stage.
Summary of the invention
Technical problem to be solved by this invention is, overcomes the deficiencies in the prior art, and a kind of antihypertensive peptide composition is provided.
Antihypertensive peptide composition of the present invention is achieved by following technical proposals, comprises that following components in weight portion array becomes: Semen phaseoli radiati peptide 40～70%, corn peptide 30～60%.
Antihypertensive peptide composition of the present invention is become by following components in weight portion array: Semen phaseoli radiati peptide 40～50%, corn peptide 35～45%, soybean peptide 15～25%.
Antihypertensive peptide composition of the present invention is become by following components in weight portion array: Semen phaseoli radiati peptide 40～50%, corn peptide 35～45%, the Radix Astragali 5～10%.
Angiotensin converting enzyme (Agiotensin-Converting Enzyme ACE) is a kind of Zn of containing
2+The carboxylic dipeptidase of prothetic group, it is a kind of multifunctional enzyme, plays important effect in blood pressure regulating.Angiotensin-convertion enzyme inhibitor (ACEI) is a kind of effective regulating measure.At present, there have been many chemosynthesis class ACE inhibitor to be applied to clinical.Yet this class Altace Ramipril is not long action time, can make the blood pressure bounce-back after the drug withdrawal; And this class medicine is absorbed with excretory speed comparatively fast, discharges easily infringement renal function through kidney, and certain side effect is arranged.Therefore, seek a kind of novel depressor safe, long-acting, that have no side effect and become an exigence.We filter out the polypeptide raw material and the plant extract of hypotensive effect by a large amount of in-vitro screening experiment (suppressing ACE activity screen method), and by the zoopery proof tangible hypotensive effect are arranged.
Studies show that both at home and abroad some small peptides in the food protein enzymatic hydrolysate have physiological regulation function widely, promote calcium absorption, blood pressure lowering, cholesterol reducing, immunomodulating etc., the effect that can produce similar hormonal activity material.The inhibiting peptide of tonin that particularly has hypotensive activity has become the importance of biologically active peptide research field.The blood pressure lowering peptide of food source is safe, has no side effect; Can play hypotensive effect to the hyperpietic, normotensive people is not had hypotensive effect; And the source is abundant, comprising plant, marine organisms etc.; Effective antihypertensive compositions content height; Simultaneously, the present invention combines 5,000 years culture of health preserving of the nutrition of polypeptide culture and China, therefore has exploitation and is worth.
Brief description zoopery of the present invention:
Spontaneous hypertensive rat (SHR), with 4, the dosage of 6g/kg body weight irritates stomach, before gavaging and after gavaging 0,2,4,6,8h measure arteria caudalis systolic pressure (the systolic blood pressure of rat with arteria caudalis pulse manometry respectively, SBP), experimental design is SHR negative control group (normal saline group), positive controls (captopril 7 mg/kg), SHR medicine group (two kinds of various dose), and every group of rat of totally three big groups is 4.The blood pressure dynamic change of 12h behind the stomach is irritated in research, investigates the medicine within a short period of time of the blood pressure lowering situation to the essential hypertension rat, to judge the antihypertensive effect of medicine.
1. laboratory animal and instrument:
32 of spontaneous hypertension rats (SHR), body weight is 180～220g.Electronic balance (SL-1001 type, 0.1g, Shanghai Min Qiao Electronic Instruments Plant); RBP-1 type rat blood pressure meter (Sino-Japanese Friendship Hospital's production).
2. experimental program
Sample 1: Semen phaseoli radiati peptide 5g, corn peptide 3g, soybean peptide 2g.
Sample 2: Semen phaseoli radiati peptide 5g, corn peptide 4.5g, Radix Astragali 0.5g.
The single cage of all animals is raised, and the water of freely ingesting after 7 day quanrantine, adopts RBP-1 type rat blood pressure instrumentation to decide blood pressure, according to blood pressure level 32 SHR rats is divided into eight groups at random,
First day:
Negative control group: 4, give distilled water;
Sample 1 high dose group: 4, give high dose sample 1 (0.5g/kg);
Sample 2 high dose group: 4, give high dose sample 2 (0.5g/kg);
Positive controls: 4, give Altace Ramipril (blocking 7mg/kg in the Top).
Second day:
Negative control group: 4, give distilled water;
Sample 1 low dose group: 4, give low-dosage sample 1 (0.1g/kg);
Sample 2 low dose group: 4, give low-dosage sample 2 (0.1g/kg);
Animal is irritated stomach 1 time, irritates the long-pending 10ml/kg BW of being of body of stomach.0,2,4,6 hour blood pressure and heart rate behind the METHOD FOR CONTINUOUS DETERMINATION rat oral gavage.
3. index determining method: animal blood pressure, measurement of Heart Rate are clear-headed animal, carry out under the rest state, and Mus tail oversleeve is positioned over the root of Mus tail, select the suitable oversleeve of degree of tightness for use.Oversleeve is forced into asphygmia about 20mmHg place afterwards with the speed inflation of about 20-30mmHg/s.Each certain hour at interval of measuring, continuous three readings of recorded heart rate variation≤10 times/minute, blood pressure≤6mmHg are got its mean.
The specific embodiment
Below in conjunction with embodiment the present invention is described further.
According to different crowd, the product mechanism of action, products characteristics design, interpolation adjuvant, auxiliary element are prepared into tablet or electuary.
Each embodiment such as following table, component unit in the table: g
| The Semen phaseoli radiati peptide | Corn peptide | Soybean peptide | The Radix Astragali | |
| Embodiment 1 | ?70 | ?30 | ?0 | ?0 |
| Embodiment 2 | ?50 | ?30 | ?20 | ?0 |
| Embodiment 3 | ?50 | ?45 | ?0 | ?5 |
| Embodiment 4 | ?45 | ?40 | ?15 | ?0 |
| Embodiment 5 | ?60 | ?32 | ?0 | ?8 |
Dosage form of the present invention can be selected electuary or powder for use, and raw material sieves by after pulverizing, add adjuvant and mix, according to dosage require packing then, pack at last and form electuary or powder, the temperature of preparation is controlled at below 30 ℃, and quite humidity (RH) is controlled at below 45%.
Claims (3)
1. an antihypertensive peptide composition is characterized in that, comprises that following components in weight portion array becomes: Semen phaseoli radiati peptide 40～70%, corn peptide 30～60%.
2. antihypertensive peptide composition according to claim 1 is characterized in that, is become by following components in weight portion array: Semen phaseoli radiati peptide 40～50%, corn peptide 35～45%, soybean peptide 15～25%.
3. antihypertensive peptide composition according to claim 1 is characterized in that, is become by following components in weight portion array: Semen phaseoli radiati peptide 40～50%: corn peptide 35～45%: the Radix Astragali 5～10%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA200810052806XA CN101559179A (en) | 2008-04-18 | 2008-04-18 | Antihypertensive peptide composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA200810052806XA CN101559179A (en) | 2008-04-18 | 2008-04-18 | Antihypertensive peptide composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101559179A true CN101559179A (en) | 2009-10-21 |
Family
ID=41218271
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA200810052806XA Pending CN101559179A (en) | 2008-04-18 | 2008-04-18 | Antihypertensive peptide composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101559179A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105327330A (en) * | 2015-12-04 | 2016-02-17 | 天津市百奥生物技术有限公司 | Composition with blood pressure reducing effect and preparation method thereof |
| CN107007812A (en) * | 2017-04-05 | 2017-08-04 | 江苏大学 | A kind of method for extending captopril hypotensive efficacy time |
| CN111887388A (en) * | 2020-06-12 | 2020-11-06 | 天津科技大学 | Processing method of antihypertensive polypeptide composite rice |
-
2008
- 2008-04-18 CN CNA200810052806XA patent/CN101559179A/en active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105327330A (en) * | 2015-12-04 | 2016-02-17 | 天津市百奥生物技术有限公司 | Composition with blood pressure reducing effect and preparation method thereof |
| CN105327330B (en) * | 2015-12-04 | 2019-01-08 | 天津市百奥生物技术有限公司 | A kind of composition and preparation method thereof with antihypertensive effect |
| CN107007812A (en) * | 2017-04-05 | 2017-08-04 | 江苏大学 | A kind of method for extending captopril hypotensive efficacy time |
| CN111887388A (en) * | 2020-06-12 | 2020-11-06 | 天津科技大学 | Processing method of antihypertensive polypeptide composite rice |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109207543A (en) | A kind of ox bone collagen protein peptides and preparation method and purposes | |
| CN101711786B (en) | Preparation used for relieving osteoarthropathy and enhancing immunity | |
| CN106174479A (en) | A kind of geriatric nutrition powder and preparation method thereof | |
| CN102405951B (en) | Semen cassiae sopherae slimming, lipid reducing, pressure lowering and glucose lowering biscuit and production process thereof | |
| CN102949710A (en) | Pharmaceutical composition or healthcare product for increasing bone mineral density and preparation method of pharmaceutical composition or healthcare product | |
| CN107184966A (en) | A kind of pharmaceutical composition for preventing and treating diabetes and its complication | |
| CN105661515B (en) | A kind of ferment lozenge for preventing three high diseases and preparation method thereof | |
| CN102573885A (en) | Composition having lipolysis-promoting effect | |
| CN101559179A (en) | Antihypertensive peptide composition | |
| CN106942578A (en) | A kind of natural meals for controlling purine intake and promoting uric acid excretion | |
| CN1902189A (en) | Plant-origin beta3-adrenoceptor agonist and use of the same | |
| CN101757470A (en) | Blood fat lowering composition | |
| CN110074392A (en) | A kind of Antialcoholic liver-protecting nourishing the stomach shield intestines composition and preparation method thereof | |
| CN101524153A (en) | Health-care wheat flour beneficial for diabetes patients | |
| CN101336705B (en) | Health food and its preparation method | |
| CN107537028A (en) | A kind of while auxiliary hyperglycemic and the formula of hypotensive and preparation method thereof | |
| CN100420457C (en) | Tablet containing F.tataricum and spirulina spp. , and its preparation method | |
| CN1763091A (en) | Mumia protein and its production process | |
| CN113209217A (en) | Traditional Chinese medicine composition for resisting physical fatigue and preparation method thereof | |
| CN105963327A (en) | Vitamin K2 composition for prevention and treatment of liver function impairment | |
| CN1150917C (en) | Medicine containing active components of Rhodiola crennulata root and preparing process thereof | |
| CN105995980A (en) | Composition with weight management function and preparation method thereof | |
| CN103316273B (en) | Improve animal immunizing power and promote the Chinese medicine composition of growth of animal | |
| CN111227229A (en) | Plant source nutrition powder and preparation method and edible method thereof | |
| JP6338113B2 (en) | Lean body weight increase agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20091021 |